{
  "paper": {
    "doi": null,
    "pmcid": "PMC12758042",
    "title": "Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of BRCA1 or BRCA2 Pathogenic Variants",
    "authors": [],
    "journal": null,
    "year": null,
    "study_type": "narrative review",
    "eco_type": null
  },
  "extraction_provenance": {
    "extraction_pipeline": {
      "name": "medlit_pass1_extract",
      "version": "0.1.0",
      "git_commit": "f5da8dd9b8dd84ea4823af0e58537841df333399",
      "git_commit_short": "f5da8dd",
      "git_branch": "ingest-refactor",
      "git_dirty": true,
      "repo_url": "https://github.com/org/medlit"
    },
    "models": {
      "llm": {
        "name": "claude-sonnet-4-20250514",
        "version": ""
      }
    },
    "prompt": {
      "version": "v1",
      "template": "medlit_extraction_v1",
      "checksum": "sha256:f94cc0ab23940d18"
    },
    "execution": {
      "timestamp": "2026-02-23T22:31:17.241231Z",
      "hostname": "unknown",
      "python_version": "3.13.3",
      "duration_seconds": 51.16
    },
    "entity_resolution": null,
    "model_info": null
  },
  "entities": [
    {
      "id": "BRCA1",
      "class": "Gene",
      "name": "BRCA1",
      "synonyms": [
        "BRCA1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:1100",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "BRCA2",
      "class": "Gene",
      "name": "BRCA2",
      "synonyms": [
        "BRCA2"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:1101",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "breast_cancer",
      "class": "Disease",
      "name": "breast cancer",
      "synonyms": [
        "breast cancer",
        "invasive breast cancer"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0006142",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "ovarian_cancer",
      "class": "Disease",
      "name": "ovarian cancer",
      "synonyms": [
        "ovarian cancer"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0029925",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "tamoxifen",
      "class": "Drug",
      "name": "tamoxifen",
      "synonyms": [
        "tamoxifen"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "10324",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "raloxifene",
      "class": "Drug",
      "name": "raloxifene",
      "synonyms": [
        "raloxifene"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "56946",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "exemestane",
      "class": "Drug",
      "name": "exemestane",
      "synonyms": [
        "exemestane"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "69278",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "anastrozole",
      "class": "Drug",
      "name": "anastrozole",
      "synonyms": [
        "anastrozole"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "84857",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "letrozole",
      "class": "Drug",
      "name": "letrozole",
      "synonyms": [
        "letrozole"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "114979",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "denosumab",
      "class": "Drug",
      "name": "denosumab",
      "synonyms": [
        "denosumab"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1043562",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "bilateral_salpingo_oophorectomy",
      "class": "Procedure",
      "name": "bilateral salpingo-oophorectomy",
      "synonyms": [
        "BSO",
        "bilateral salpingo-oophorectomy",
        "risk-reducing salpingo-oophorectomy",
        "RRSO"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0195471",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "prophylactic_mastectomy",
      "class": "Procedure",
      "name": "prophylactic mastectomy",
      "synonyms": [
        "prophylactic bilateral mastectomy",
        "PBM",
        "risk-reducing mastectomy",
        "RRM"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0024881",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "magnetic_resonance_imaging",
      "class": "Procedure",
      "name": "magnetic resonance imaging",
      "synonyms": [
        "MRI",
        "contrast-enhanced breast magnetic resonance imaging"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0024485",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "SERMs",
      "class": "Drug",
      "name": "selective estrogen receptor modulators",
      "synonyms": [
        "SERMs",
        "selective estrogen receptor modulators"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0360135",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "aromatase_inhibitors",
      "class": "Drug",
      "name": "aromatase inhibitors",
      "synonyms": [
        "AIs",
        "aromatase inhibitors"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0593802",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    }
  ],
  "evidence_entities": [
    {
      "id": "paper_1:introduction:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_1",
      "text": "approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2. These mutations greatly increase cancer risks",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_2",
      "text": "Annual magnetic resonance imaging (MRI) remains the most sensitive screening tool for early breast cancer detection in high-risk individuals",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_3",
      "text": "Selective estrogen receptor modulators (SERMs) and aromatase inhibitors have shown potential as chemopreventive agents",
      "confidence": 0.8,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:4:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_4",
      "text": "Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:results:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "results_1",
      "text": "Carriers of pathogenic BRCA2 variants have a lifetime risk of developing breast cancer ranging from 38% to 84%, while the risk of developing ovarian cancer ranges from 16.5% to 27.0%",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:results:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "results_2",
      "text": "Carriers of BRCA1 mutation may have higher risk of both breast and ovarian cancers",
      "confidence": 0.8,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:results:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "results_3",
      "text": "prophylactic bilateral mastectomy (PBM) which has been shown to reduce the incidence of breast cancer by approximately 90%",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:results:4:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "results_4",
      "text": "those who underwent risk-reducing BSO had a lower risk of first breast cancer diagnosis compared with those who did not: 7% versus 23% in BRCA2 carriers (HR: 0.36 (95% CI: 0.16 - 0.82)) and 14% versus 20% in BRCA1 carriers (HR: 0.63 (95% CI: 0.41 - 0.96))",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:results:5:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "results_5",
      "text": "The adjusted HRs were 0.38 (95% CI: 0.27 - 0.55) for BRCA1 carriers and 0.33 (95% CI: 0.22 - 0.50) for BRCA2 carriers",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:results:6:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "results_6",
      "text": "exemestane use was associated with significant reduction in invasive breast cancers in all study subgroups (HR: 0.35, 95% CI: 0.18 - 0.70)",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "narrative review",
      "eco_type": null,
      "source": "extracted"
    }
  ],
  "relationships": [
    {
      "subject": "BRCA1",
      "predicate": "INCREASES_RISK",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:1:llm",
        "paper_1:results:2:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "BRCA2",
      "predicate": "INCREASES_RISK",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:1:llm",
        "paper_1:results:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "BRCA1",
      "predicate": "INCREASES_RISK",
      "object": "ovarian_cancer",
      "evidence_ids": [
        "paper_1:results:2:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "BRCA2",
      "predicate": "INCREASES_RISK",
      "object": "ovarian_cancer",
      "evidence_ids": [
        "paper_1:results:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "magnetic_resonance_imaging",
      "predicate": "INDICATES",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:2:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "SERMs",
      "predicate": "TREATS",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "mechanism": "chemoprevention"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "aromatase_inhibitors",
      "predicate": "TREATS",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "mechanism": "chemoprevention"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "bilateral_salpingo_oophorectomy",
      "predicate": "TREATS",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:4:llm",
        "paper_1:results:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "mechanism": "risk reduction"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "bilateral_salpingo_oophorectomy",
      "predicate": "TREATS",
      "object": "ovarian_cancer",
      "evidence_ids": [
        "paper_1:introduction:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "mechanism": "risk reduction"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "prophylactic_mastectomy",
      "predicate": "TREATS",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:introduction:4:llm",
        "paper_1:results:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "mechanism": "risk reduction"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "tamoxifen",
      "predicate": "SUBTYPE_OF",
      "object": "SERMs",
      "evidence_ids": [
        "paper_1:results:5:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "raloxifene",
      "predicate": "SUBTYPE_OF",
      "object": "SERMs",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "exemestane",
      "predicate": "SUBTYPE_OF",
      "object": "aromatase_inhibitors",
      "evidence_ids": [
        "paper_1:results:6:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "anastrozole",
      "predicate": "SUBTYPE_OF",
      "object": "aromatase_inhibitors",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "letrozole",
      "predicate": "SUBTYPE_OF",
      "object": "aromatase_inhibitors",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "tamoxifen",
      "predicate": "TREATS",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:results:5:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "mechanism": "chemoprevention"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "exemestane",
      "predicate": "TREATS",
      "object": "breast_cancer",
      "evidence_ids": [
        "paper_1:results:6:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "mechanism": "chemoprevention"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    }
  ],
  "notes": [
    "This is a narrative review summarizing evidence on screening and risk reduction strategies for BRCA1/BRCA2 carriers",
    "The paper discusses multiple interventions including surveillance, chemoprevention, and risk-reducing surgeries",
    "Evidence is primarily from observational studies and clinical trials referenced in the review"
  ]
}